Abcam, headquartered in Cambridge, United Kingdom, is a leading provider of life science research tools. Established in 1998 by Jonathan Milner, a PhD scientist, the company aims to serve the global scientific community by providing high-quality antibodies, proteins, assay kits, and other reagents. Abcam started as a catalog company, publishing its first catalog in 1999.

The catalog quickly gained popularity for its large selection of antibodies designed for various research applications. Over the years, Abcam expanded its product range to include proteins, assays, and other tools while maintaining a focus on quality and customer satisfaction. Currently, Abcam's headquarters are located in a state-of-the-art facility in Cambridge, UK.

The building is equipped with cutting-edge research and production facilities, enabling the company to maintain its high standards of quality control and ensure prompt delivery of products to customers worldwide. Operating on a global scale, Abcam serves researchers in academia, biotechnology, and pharmaceutical companies. The company has a strong international presence, with subsidiaries and offices in the United States, Japan, China, Switzerland, Germany, and Australia, to name a few.

Abcam also has numerous distribution partnerships with local companies, enabling it to reach customers in more than 130 countries. Abcam's market position is highly favorable, with the company frequently cited as one of the leading suppliers of research tools in the industry. Its extensive product portfolio, excellent customer service, and commitment to innovation have helped it establish a strong reputation and gain a significant market share.

In terms of global sales, Abcam has consistently reported strong financial performance. In its latest financial report, the company announced revenue of over £258 million. Additionally, Abcam has made notable acquisitions, such as the purchase of AxioMx in 2014, which expanded its capabilities in recombinant antibody engineering.

Recent significant events for Abcam include the launch of new products, collaborations with research institutions and industry partners, and strategic acquisitions. These initiatives have helped the company expand its customer base and strengthen its position in the market. As of the latest updates, Abcam continues to experience steady growth and expansion.

With a dedicated workforce of over 1,500 employees worldwide and a commitment to advancing scientific research, the company remains at the forefront of the life science research tools industry, contributing to breakthrough discoveries and advancements in the field